Coronavirus Infections
Conditions
Keywords
Coronavirus infection, Lopinarvir plus ritonavir, Arbidol, Efficacy
Brief summary
The study explores the efficacy of lopinavir plus ritonavir and arbidol in treating with novel coronavirus infection. As a result this study would provide evidence for the clinical usage of these drugs in the future .
Detailed description
This is a phase IV, open-labelled, randomized controlled clinical trial. A total of 125 cases who are novel coronavirus positive are planned to be recruited. These cases are randomized into 3 groups: in group A（Standard treatment+lopinavir/ritonavir）, 50 cases are given ordinary treatment plus a regimen of lopinavir (200mg) and ritonavir (50mg) (oral, q12h, every time 2 tablets of each, taking for 7-14 days). In group B（Standard treatment+arbidol） , 50 cases are given ordinary treatment plus a regimen of arbidol (100mg) (oral, tid, 200mg each time, taking for 7-14 days). In group C（Standard treatment）, 25 cases are only given ordinary treatment. The observation duration is 21 days. Patients will be followed up at baseline (day 0) and day 2, 4, 7, 10,14, 21 after receiving indicated treatment. The primary observed indicators include viral nucleic in acid nose / throat swab, body temperature, respiratory rate, oxygen saturation of blood, chest imaging. The secondary observed indicators include but not limited to blood pressure, heart rate, blood routine test, liver and kidney function, myocardial enzyme, flow cytometry classification and counting, cytokines, other infection indicators, conditions and parameters of auxiliary respiration, the total days in hospital, exacerbation and mortality.
Interventions
As indicated in arm/group descriptions
DRUGArbidol
As indicated in arm/group descriptions
Sponsors
Guangzhou 8th People's Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
125 patients are randomized in 3 groups (2:2:1). In group A(Standard treatment+lopinavir/ritonavir) , 50 cases are given ordinary treatment plus a regimen of lopinavir (200mg) and ritonavir (50mg) (oral, q12h, every time 2 tablets of each, taking for 7-14 days). In group B (Standard treatment+arbidol), 50 cases are given ordinary treatment plus a regimen of arbidol (100mg) (oral, tid, 200mg each time, taking for 7-14 days). In group C (Standard treatment）, 25 cases are only given ordinary treatment.
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* In sputum, throat swab, lower respiratory tract secretion, blood and other samples, the nucleic acid of the novel coronavirus was positive, or the sequencing of the virus gene was highly homologous with the known novel coronavirus * Age is between 18-80 years old, the weight is more than 30kg, and there is no limit for men and women * The following conditions were met: creatinine ≤ 110 umol / L, creatinine clearance rate (EGFR) ≥ 60 ml / min / 1.73m2, AST and ALT ≤ 5 × ULN, TBIL ≤ 2 × ULN; * The subjects should fully understand the purpose, nature, method and possible reaction of the study, voluntarily participate in the study and sign the informed consent.
Exclusion criteria
* Have a clear history of lopinavir or ritonavir or arbidol allergy * Severe nausea, vomiting, diarrhea and other clinical manifestations affect the oral or absorption of the drugs * At the same time, take drugs that may interact with lopinavir or ritonavir or arbidol * Patients with serious underlying diseases, including but not limited to heart disease (including history of angina pectoris or coronary heart disease or myocardial infarction, atrioventricular block), lung, kidney, liver malfunction and mental diseases that cannot be treated together * ancreatitis or hemophilia * Pregnant and lactating women * Suspected or confirmed history of alcohol and drug abuse * Participated in other drug trials in the past month * The researchers judged that patients were not suitable for the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The rate of virus inhibition | Day 0, 2, 4, 7, 10, 14 and 21 | Novel coronaviral nucleic acid is measured in nose / throat swab at each time point. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The disease prorogation-respiratory function 3 | Day 0, 4, 7, 10, 14 and 21 | Chest imaging will be taken at each time point. |
| The disease prorogation-temperature | Day 0 till day 21 | Body temperature will be followed everyday during time frame. |
| The disease prorogation-respiratory function 1 | Day 0 till day 21 | Respiratory rate will be followed everyday during time frame. |
| The disease prorogation-respiratory function 2 | Day 0 till day 21 | Oxygen saturation of blood will be followed everyday during time frame. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Patients health condition-blood routine test | Day 0, 4, 7, 10, 14 and 21 | Flow cytometry classification and counting and cytokines will be measured at each time point. |
| Patients health condition-routine test | Day 0 till day 21 | Blood pressure and heart rate will be followed everyday during time frame. |
| Patients health condition-liver function | Day 0, 4, 7, 10, 14 and 21 | Liver function will be assessed as AST, ALT and TBIL at each time point. |
| Patients health condition-kidney function | Day 0, 4, 7, 10, 14 and 21 | Kidney function will be assessed as eGFR and creatine clearance rate at each time point. |
| Patients health condition-other blood routine test | Day 0, 4, 7, 10, 14 and 21 | Blood routine and myocardial enzyme will be measured at each time point. |
Countries
China
Outcome results
None listed